Market closed·Syncing…
Market closed · Close · 19 Nov

Nureca Limited NURECAshare price and chart

Nureca closed at ₹298.65 on 19 November 2026, down 1.22% on the day. The 52-week range is ₹204.00 to ₹376.00.

₹298.65The price one share last traded at, in rupees.▼ 1.22% · ₹3.69
52-wk low ₹20455% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹376

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on NURECA

Real prices, every charge counted. Pick one or write your own.

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
41.8Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
56.3%Near average
today 56.3%20d avg 54.6%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.▼ 7.5%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+4.2%1 monthHow much the share price has changed over the period.▼ 9.2%3 monthsHow much the share price has changed over the period.▼ 5.8%1 yearHow much the share price has changed over the period.+11.3%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.32.1%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹285 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.60.7xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.1.1%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.1.52xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.3.3%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.34.1xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.01xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-2.4%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Medical Equipment & Supplies · 16 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.60.7vs 28.23 median
Cheapest: GKB 6.05Priciest: TARSONS 215.39
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.2.74%vs 7.06% median
Lowest: MHHL -4.14%Highest: AVIENCE 17.16%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.55.08%vs 17.5% median
Lowest: FABTECH -24.2%Highest: NURECA 55.08%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 21 Oct 2026), sales rose 55.1% from a year earlier to ₹58.5 cr and profit rose 11.7% to ₹4.1 cr.

Going well
  • Operating margin rose from -13.5% in FY23 to 0.1% in FY26.
  • Promoter holding rose 6.6 points over 7 quarters (64.06% to 70.68%).
Worth watching
  • Reported a loss in FY24.
  • Return on equity stayed under 10% from FY24 to FY26 (highest 1.1%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 18 results, the share rose on 6 and fell on 12, and moved by 3% or more on 10.

+10%
-10%
Q4 FY22Q4 FY23Q4 FY24Q4 FY25Q2 FY27

Q2 FY27: results filed 21 Oct 2026. The share went from its close on 19 Oct 2026 to its close on 22 Oct 2026 +6.42%.

Dividend historyCash the company has paid per share, year by year.

₹1,005 in 2022
Paid 2 of 2 yrs
what 2022's payouts come to on ₹1 lakh at today's price · nothing declared in the last twelve months
What each year paid, on ₹1 lakh
670
1,005
21
22

2022 paid ₹3.00 per share, about ₹1,005 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
-27.4%a year, over 5 years
1 yr
+13.2%
3 yr
-6.2%
5 yr
-27.4%

Held for 5 years this compounded at -27.4% a year. The last twelve months were up +13.2%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
70.68%promoter holding, as of 2026-09-30+0.7 pts since 2021
Promoter share since listing
2021-0970.68% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
70.7%
28.9%
Promoter70.7%Foreign (FII)0.2%Domestic (DII)0.2%Public & others28.9%
Who is buying, who is leavingJun 25 to Sep 26
Promoter70.7%+6.4 pts
Foreign (FII)0.2%+0.1 pts
Domestic (DII)0.2%+0.2 pts

Each line is that holder's share of all shares over the last 7 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Updates12-Nov-2026

Nureca Limited has informed the Exchange regarding 'Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015 ( PIT Regulations )'.

Credit Rating03-Nov-2026

Nureca Limited has informed the Exchange about Credit Rating

Copy of Newspaper Publication22-Oct-2026

Nureca Limited has informed the Exchange about Copy of Newspaper Publication

Press Release21-Oct-2026

Nureca Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Nureca records highest quarterly revenue in last 20 quarters ; Q2 revenue rises 55% to Rs. 58.53 crore ".

Press Release21-Oct-2026

Nureca Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Nureca records highest quarterly revenue in last 20 quarters; Q2 revenue rises 55% to ₹58.53 crore".

Press Release21-Oct-2026

Nureca Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Nureca records highest quarterly revenue in last 20 quarters; Q2 revenue rises 55% to ₹58.53 crore"

Press Release21-Oct-2026

Nureca Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Nureca records highest quarterly revenue in last 20 quarters; Q2 revenue rises 55% to ₹58.53 crore".

Outcome of Board Meeting21-Oct-2026

Nureca Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

General Updates17-Oct-2026

Nureca Limited has informed the Exchange about General Updates

Certificate under SEBI (Depositories and Participants) Regulations, 201815-Oct-2026

Nureca Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Updates01-Oct-2026

Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'.

Updates30-Sep-2026

Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'.

Trading Window29-Sep-2026

Nureca Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Updates29-Sep-2026

Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'.

Updates28-Sep-2026

Nureca Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'.

Backtest idea · NURECAMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on NURECA
Backtest idea · NURECALower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on NURECA
Backtest idea · NURECASupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on NURECA
Your own ideaWrite a rule for NURECA in plain English“Buy NURECA when …”
Start writing
Buy the dip on NURECABuy when RSI(14) drops below 30
52-week high breakout on NURECABuy when closes at a 52-week high
Golden cross on NURECABuy when 50-day EMA crosses above 200-day
Stochastic oversold on NURECABuy when stochastic %K drops below 20
Pullback in an uptrend on NURECABuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹285 cr
Larger than 38% of 16 peers
sector middle ₹560 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
60.7x
Higher than 75% of 12 peers
sector middle 28.2x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
1.5x
Lower than 79% of 14 peers
sector middle 2.4x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
1.1%
Lowest of 5 peers
sector middle 9.1%
FY23 -4.2%FY26 1.1%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
3.3%
Lower than 92% of 12 peers
sector middle 12.3%
FY23 -5.2%FY26 3.3%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.01
Lower than 86% of 14 peers
sector middle 0.20
FY23 0.02FY26 0.00
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 38% of 16 peers
sector middle 0.0%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+55.1%
Highest of 9 peers
sector middle +17.5%
FY23 -56.4%FY26 34.0%

Peers are the listed companies in the exchange's own industry group: Medical Equipment & Supplies. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.0.1%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+11.7%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹147 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹2 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹1.4 as profit. Other income added ₹5.5.

Where it wentPer ₹100 of sales
Running costs₹99.9Depreciation₹1.4Interest₹0.9Tax₹2.0Profit₹1.4
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+9.7%-+55.1%
Profit--+11.7%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹2 Cr, after ₹7 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹3 Cr
Investing+₹14 Cr
Lenders and shareholders-₹20 Cr
Net change in cash-₹2 Cr
Operating cash per ₹100 of profit
₹-2,245FY25₹159FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.-56.4%-17.4%19.4%34.0%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.-13.5%-11.1%-6.9%0.1%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.-7.4%-2.0%0.7%1.4%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.-4.2%-0.9%0.4%1.1%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.-5.2%-1.1%1.3%3.3%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.02x0.00x0.01x0.00x
Interest coverHow many times the company's profit before interest could pay its interest bill.-20.4x-4.0x2.1x4.8x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · NURECAStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on NURECA
Backtest idea · NURECAPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on NURECA
Backtest idea · NURECABuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on NURECA
Backtest idea · NURECA52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on NURECA
Backtest idea · NURECAGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on NURECA
MACD momentum on NURECABuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on NURECABuy when closes below the lower Bollinger band
Supertrend rider on NURECABuy when supertrend turns up
Buy the dip on NURECABuy when RSI(14) drops below 30
52-week high breakout on NURECABuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Medical Equipment & Supplies
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
MOLBIO
Molbio Diagnostics Limited
17,590 cr-12.2x--0.22--0.00%
POLYMED
Poly Medicure Limited
16,933 cr53.2x5.2x10.8%13.7%0.1214.8%+30.8%0.21%
TARSONS
Tarsons Products Limited
1,616 cr215.4x2.5x2.3%4.5%0.611.6%+20.8%0.00%
FISCHER
Fischer Medical Ventures Limited
1,496 cr87.9x3.2x8.1%11.5%0.114.3%+24.5%0.22%
LAXMIDENTL
Laxmi Dental Limited
1,060 cr32.7x4.0x12.8%13.1%0.0011.0%+10.0%0.00%
QLINE
Q-Line Biotech Limited
952 cr12.8x2.0x-19.5%0.2715.4%-0.00%
DENTALKART
Vasa Denticity Limited
840 cr69.7x4.4x-9.1%0.003.8%-0.00%
FABTECH
Fabtech Technologies Limited
593 cr15.7x1.4x9.1%11.3%0.079.2%-24.2%0.45%
OSELDEVICE
Osel Devices Limited
527 cr23.8x2.3x-23.9%0.649.5%-0.34%
QMSMEDI
QMS Medical Allied Services Limited
331 cr-3.6x--0.86--0.29%
NURECA
Nureca Limited
285 cr60.7x1.5x1.1%3.3%0.012.7%+55.1%0.00%
APRAMEYA
Aprameya Engineering Limited
238 cr-------0.00%
MADHAVBAUG
Vaidya Sane Ayurved Laboratories Limited
162 cr41.3x2.3x-16.9%0.183.4%+17.5%0.00%
AVIENCE
Avience Biomedicals Limited
138 cr12.2x2.2x-23.2%0.4417.2%-0.00%
MHHL
Mohini Health & Hygiene Limited
49 cr-0.5x--9.9%1.62-4.1%+50.2%0.00%
GKB
GKB Ophthalmics Limited
30 cr6.0x----3.2%+8.5%0.00%
GML
Galaxy Medicare Limited
26 cr8.7x0.6x-11.2%0.107.1%+7.8%4.15%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-9.8
+6.2
-30.0
+28.9
+5.6
-15.7
+44.7
-3.4
+10.5
-19.9
+1.6
·
-3.0%
11m
2025
+2.2
-14.4
-14.5
+9.2
+10.6
+11.5
-12.6
-3.6
-4.0
+13.5
+10.8
+6.3
+8.8%
2024
-10.9
-13.0
-23.1
+13.0
-8.1
+1.3
+0.9
+8.6
+23.6
-18.8
-4.1
-0.2
-33.9%
2023
-22.4
-12.0
-12.0
+11.4
-5.5
+16.4
-8.0
-4.3
+3.8
-0.4
+7.2
+19.2
-14.1%
2022
-13.4
-20.5
-0.9
-5.3
-19.4
-5.3
+3.4
-2.5
-11.1
-12.7
-34.7
-1.5
-75.2%
2021
·
·
-11.3
+101.3
+29.5
+1.1
+8.8
-2.4
-3.5
+6.5
-13.9
+34.6
+195.8%
10m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2025-10-29SWATHITHA SIVAKUMAR · bulkSELL77,761₹263.96₹2.05 Cr
2025-01-15COPTHALL MAURITIUS INVESTMENT LIMITED · bulkBUY1,16,711₹401.94₹4.69 Cr
2025-01-15AAKRAYA RESEARCH LLP · bulkSELL63,937₹409.84₹2.62 Cr
2025-01-15AAKRAYA RESEARCH LLP · bulkBUY63,937₹409.49₹2.62 Cr
2025-01-14ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED · bulkSELL65,679₹363.99₹2.39 Cr
2025-01-14ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED · bulkBUY51,679₹360.28₹1.86 Cr
2025-01-10N V INVESTMENTS · bulkBUY1,58,000₹358.81₹5.67 Cr
2025-01-10MUDUPULAVEMULA SURENDRANADHA REDDY · bulkBUY95,867₹362.11₹3.47 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test NURECA. “Buy NURECA when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free